Tomas Griebling, MD
Urology · Kansas City, KSNPI 1386743672
Payments from drug & device makers
Across 8 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$152
- C. R. Bard, Inc. & Subsidiaries$96
- BD$31
- Convatec Inc.$17
- Medtronic$15
Across 8 payments — averaging $1004.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$8K
What the payments were for
- Food & beverage$312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $152 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $96 |
| BD | 2 | $31 |
| Convatec Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700$119
How this compares
$312 in reported general payments places this provider in the 10th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 421 | $286,913 |
| GemtesaVibegron | 127 | $90,430 |
| ElmironPentosan Polysulfate Sodium | 42 | $37,231 |
| Trospium Chloride | 205 | $17,693 |
| Trospium Chloride ErTrospium Chloride | 66 | $15,305 |
| Methenamine Hippurate | 154 | $14,367 |
| Estradiol | 147 | $9,632 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 61 | $7,586 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 21 | $5,615 |
| Oxybutynin Chloride ErOxybutynin Chloride | 147 | $4,695 |
| Solifenacin Succinate | 118 | $4,367 |
| Metronidazole | 26 | $1,555 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $1,374 |
| Tamsulosin Hcl | 103 | $1,164 |
| Hydroxyzine Hcl | 49 | $1,019 |
Paid to pharmacies, not to this prescriber.
Other urology in Kansas City
- Eugene LeeKansas City$2.2M
- Wilson MolinaKansas City$513K
- Jeffrey HolzbeierleinKansas City$341K
- Bristol WhilesKansas City$290K
- John TaylorKansas City$165K
- Joshua BroghammerKansas City$98K
- Casey KowalikKansas City$97K
- Moben MirzaKansas City$57K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.